Axovant Sciences (NASDAQ: AXON), a clinical-stage company focused on innovative gene therapies for neurological and neuromuscular diseases, today announced that ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments Momentum Movers

Axovant Sciences (AXON) Prices 30M Share Offering at $1/ShDecember 14, 2018 9:02 AM Axovant Sciences (AXON) Commences Public Offering of Common SharesDecember 13, 2018 4:57 PM Axovant Licenses Investigational Gene Therapies for GM1 Gangliosidosis, Tay-Sachs and Sandhoff Diseases from University of Massachusetts Medical SchoolDecember 13, 2018 4:01 PM